Expression of a dominant negative estrogen receptor alpha variant in transgenic mice accelerates uterine cancer induced by the potent estrogen diethylstilbestrol.

[1]  M. Villegas,et al.  Inhibition of Neu-Induced Mammary Carcinogenesis in Transgenic Mice Expressing ERΔ3, a Dominant Negative Estrogen Receptor α Variant , 2012, Hormones and Cancer.

[2]  O. Ortmann,et al.  Identification of novel transcript variants of estrogen receptor α, β and progesterone receptor gene in human endometrium , 2010, Endocrine.

[3]  J. Kim,et al.  Role of Progesterone in Endometrial Cancer , 2010, Seminars in reproductive medicine.

[4]  Leping Li,et al.  Estrogen-mediated Regulation of Igf1 Transcription and Uterine Growth Involves Direct Binding of Estrogen Receptor α to Estrogen-responsive Elements* , 2009, The Journal of Biological Chemistry.

[5]  D. Vergara,et al.  Hormonal carcinogenesis and socio‐biological development factors in endometrial cancer: A clinical review , 2008, Acta obstetricia et gynecologica Scandinavica.

[6]  Stephen Safe,et al.  Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. , 2008, Journal of molecular endocrinology.

[7]  G. Chen,et al.  Estrogen and its receptors in cancer , 2008, Medicinal research reviews.

[8]  K. Kim,et al.  Minireview: estrogen receptor-mediated rapid signaling. , 2006, Endocrinology.

[9]  A. Nardulli,et al.  Cell- and Ligand-specific Regulation of Promoters Containing Activator Protein-1 and Sp1 Sites by Estrogen Receptors α and β* , 2005, Journal of Biological Chemistry.

[10]  S. Fuqua,et al.  Estrogen receptor mutations in human disease. , 2004, Endocrine reviews.

[11]  Jean‐Luc C. Mougeot,et al.  Estrogen receptor–α messenger RNA variants that lack exon 5 or exon 7 are coexpressed with wild-type form in human endometrium during all phases of the menstrual cycle , 2004 .

[12]  R. Clarke,et al.  Expression of an estrogen receptor variant lacking exon 3 in derivatives of MCF-7 cells with acquired estrogen independence or tamoxifen resistance. , 2004, Journal of molecular endocrinology.

[13]  A. Nardulli,et al.  Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. , 2004, Molecular endocrinology.

[14]  J. Gierthy,et al.  Phenotypic changes in MCF-7 cells during prolonged exposure to tamoxifen , 2003, Molecular and Cellular Endocrinology.

[15]  K. Korach,et al.  Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) Null mice reveals hypergonadism and endocrine sex reversal in females lacking ERalpha but not ERbeta. , 2003, Molecular endocrinology.

[16]  Brad Saville,et al.  Domains of Estrogen Receptor α (ERα) Required for ERα/Sp1-Mediated Activation of GC-Rich Promoters by Estrogens and Antiestrogens in Breast Cancer Cells , 2003 .

[17]  A. Nardulli,et al.  Estrogen Receptor α and Activating Protein-1 Mediate Estrogen Responsiveness of the Progesterone Receptor Gene in MCF-7 Breast Cancer Cells , 2002 .

[18]  A. Parfitt,et al.  Reversal of Bone Loss in Mice by Nongenotropic Signaling of Sex Steroids , 2002, Science.

[19]  E. J. Lee,et al.  An estrogen receptor (ER)alpha deoxyribonucleic acid-binding domain knock-in mutation provides evidence for nonclassical ER pathway signaling in vivo. , 2002, Molecular endocrinology.

[20]  K. Korach,et al.  An estrogen receptor repressor induces cataract formation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Korach,et al.  Estrogen Receptor-α Knockout Mice Exhibit Resistance to the Developmental Effects of Neonatal Diethylstilbestrol Exposure on the Female Reproductive Tract , 2001 .

[22]  A. Nardulli,et al.  Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. , 2000, Molecular endocrinology.

[23]  A. Bollig,et al.  An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription. , 2000, Molecular endocrinology.

[24]  G. Horvath,et al.  Exon deletions and variants of human estrogen receptor mRNA in endometrial hyperplasia and adenocarcinoma. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[25]  T. Maudelonde,et al.  Expression of oestrogen receptor-alpha splicing variants and oestrogen receptor-beta in endometrium of infertile patients. , 1998, Molecular human reproduction.

[26]  L. Ossowski,et al.  Loss of an Estrogen Receptor Isoform (ERαΔ3) in Breast Cancer and the Consequences of Its Reexpression: Interference with Estrogen-Stimulated Properties of Malignant Transformation , 1997 .

[27]  K. Korach,et al.  Tissue Distribution and Quantitative Analysis of Estrogen Receptor-α (ERα) and Estrogen Receptor-β (ERβ) Messenger Ribonucleic Acid in the Wild-Type and ERα-Knockout Mouse. , 1997, Endocrinology.

[28]  J. Gustafsson,et al.  Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. , 1997, Molecular endocrinology.

[29]  E. Resnick,et al.  Specific modulation of estrogen receptor mRNA isoforms in rat pituitary throughout the estrous cycle and in response to steroid hormones , 1997, Molecular and Cellular Endocrinology.

[30]  K. Korach,et al.  Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol , 1997, Molecular carcinogenesis.

[31]  S. Shousha,et al.  Presence of exon 5-deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance. , 1997, British Journal of Cancer.

[32]  A. Klibanski,et al.  Tumor-specific expression of alternatively spliced estrogen receptor messenger ribonucleic acid variants in human pituitary adenomas. , 1997, The Journal of clinical endocrinology and metabolism.

[33]  A. Jazaeri,et al.  Estrogen receptor mRNA splice variants in pre- and postmenopausal human endometrium and endometrial carcinoma. , 1997, Gynecologic oncology.

[34]  R. Derynck,et al.  Expression of a dominant-negative type II transforming growth factor β (TGF-β) receptor in the epidermis of transgenic mice blocks TGF-β-mediated growth inhibition , 1997 .

[35]  F. Walsh,et al.  Expression of a Dominant Negative FGF Receptor Inhibits Axonal Growth and FGF Receptor Phosphorylation Stimulated by CAMs , 1997, Neuron.

[36]  J. Miyazaki,et al.  Myeloid differentiation is impaired in transgenic mice with targeted expression of a dominant negative form of retinoid X receptor β , 1997, British journal of haematology.

[37]  W. Park,et al.  Identification of a variant estrogen receptor lacking exon 4 and its coexpression with wild-type estrogen receptor in ovarian carcinomas. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  M D Shelby,et al.  Assessing environmental chemicals for estrogenicity using a combination of in vitro and in vivo assays. , 1996, Environmental Health Perspectives.

[39]  R. Maronpot,et al.  Spontaneous Lesions in Aging FVB/N Mice , 1996, Toxicologic pathology.

[40]  K. Korach,et al.  Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Korach,et al.  Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. , 1995, Molecular endocrinology.

[42]  A. Ullrich,et al.  Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. , 1995, The EMBO journal.

[43]  J. Kato,et al.  Presence of alternatively spliced-estrogen receptor mRNA variants in normal human uterine endometrium and endometrial cancer. , 1995, Endocrine journal.

[44]  K. Korach,et al.  An improved method of genomic DNA extraction for screening transgenic mice. , 1994, BioTechniques.

[45]  K. Korach,et al.  Aberrant reproductive phenotypes evident in transgenic mice expressing the wild-type mouse estrogen receptor. , 1994, Endocrinology.

[46]  K. Korach,et al.  Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Y. Wang,et al.  Identification of a dominant negative form of the human estrogen receptor. , 1991, Molecular endocrinology.

[48]  R. Jaenisch,et al.  A generic intron increases gene expression in transgenic mice , 1991, Molecular and cellular biology.

[49]  T. Roderick,et al.  FVB/N: an inbred mouse strain preferable for transgenic analyses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[50]  F. Gannon,et al.  Evidence for a previously unidentified upstream exon in the human oestrogen receptor gene. , 1991, Journal of molecular endocrinology.

[51]  R. Palmiter,et al.  Heterologous introns can enhance expression of transgenes in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. McLachlan,et al.  Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. , 1990, Cancer research.

[53]  K. Korach,et al.  Developmental pattern of estrogen receptor expression in female mouse genital tracts. , 1989, Endocrinology.

[54]  P. Chambon,et al.  The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer , 1988, Cell.

[55]  K. Korach,et al.  Immunodetection of estrogen receptor in epithelial and stromal tissues of neonatal mouse uterus. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Ham,et al.  Structural organization and expression of the mouse estrogen receptor. , 1987, Molecular endocrinology.

[57]  G. Hager,et al.  Modulation of enhancer activity by the hormone responsive regulatory element from mouse mammary tumor virus. , 1984, The EMBO journal.

[58]  B. A. Harris,et al.  Plasmids for the cloning and expression of full-length double-stranded cDNAs under control of the SV40 early or late gene promoter. , 1983, Nucleic acids research.

[59]  A. Herbst,et al.  DES-related female genital changes. , 1982, Seminars in oncology.

[60]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[61]  David Bouchez,et al.  Manipulating the Mouse Embryo , 2007 .

[62]  C. Teng,et al.  Lactoferrin gene expression and regulation: an overview. , 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[63]  J. Gustafsson,et al.  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. , 1997, Endocrinology.

[64]  Newbold Rr,et al.  Cellular and molecular mechanisms of cancers of the uterus in animals. , 1996 .

[65]  M. Tsai,et al.  The Nuclear Hormone Receptor Superfamily: Structure and Function , 1996 .

[66]  Newbold Rr,et al.  Transplacental hormonal carcinogenesis: diethylstilbestrol as an example. , 1996 .

[67]  T. Brennan,et al.  Clear cell adenocarcinoma of the vagina and cervix: incidence, undetected disease, and diethylstilbestrol. , 1988, Journal of clinical epidemiology.